Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · September 15, 2022

Long-Term Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
JAMA Oncol 2022 Sep 01;[EPub Ahead of Print], T Conroy, F Castan, A Lopez, A Turpin, M Ben Abdelghani, AC Wei, E Mitry, JJ Biagi, L Evesque, P Artru, T Lecomte, E Assenat, L Bauguion, M Ychou, O Bouché, L Monard, A Lambert, P Hammel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading